Scorpion Therapeutics
Boston, United States · Founded 2020 · $420.0M raised
- Headquarters
- Boston, Massachusetts
- Employees
- 51–200
- Founded
- 2020
- Business Model
- B2B
- Website
- scorpiontx.com
- Total Funding
- $420.0M
- Last Round
- $150.0M Series CJul 2024
- Rounds
- 3
About
Scorpion Therapeutics is a clinical-stage precision oncology company developing transformational targeted therapies for patients with cancer. Founded in 2020, the company built a proprietary technology platform to identify and drug cancer-driving mutations. Its lead program STX-478, a mutant-selective PI3Kα inhibitor, was acquired by Eli Lilly in early 2025.
Summary
Scorpion Therapeutics is a Biotech company based in Boston, United States, founded in 2020. It has raised $420.0M in total across 3 rounds, most recently a $150.0M Series C round in Jul 2024. Investors include Atlas Venture, Vida Ventures and Frazier Life Sciences.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Funding History
Jul 2024
Sign up to see all 3 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies

Global fertility clinics platform
Biopharmaceutical services company

Specialty pharmaceutical company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...

Google-backed biotechnology company focused on understanding the biology of aging to develop inte...